What Enbrel needs to do after its patent win
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
Go or no go? Karyopharm awaits a verdict on selinexor
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Abbvie manoeuvres to defend Humira to the last
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
